(11/5, Fiore) reports on a study presented at the American Society of Nephrology 45th Annual Meeting and published online in the New England Journal of Medicine finding that "cinacalcet won't lower the risk of death or major cardiovascular events in chronic kidney disease patients who have secondary hyperparathyroidism." The study found "no differences in the proportion of dialysis-dependent patients who reached the primary composite endpoint (death, myocardial infarction, or heart failure) who took the drug or placebo (48.2% versus 49.2%, P=0.11)" in the "Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial of 3,883 patients with moderate-to-severe secondary hyperparathyroidism who were having dialysis." The study noted that there was "a lower-than-anticipated event rate, which required prolongation of follow-up time."
No comments:
Post a Comment